Silexion Therapeutics Corp (SLXN) Reports Q3 Loss of $2.5M, Down From $3.3M

Silexion reported Q3 net loss of approximately $2.5M versus $3.3M a year earlier, down 24.2%. Cash and cash equivalents were $4.8M at September 30, 2026; the company also reported first-patient dosing in its SIL204 Phase 2/3 trial.Material DetailsContext by AI AnalystSilexion is at an early clinica…